Active, not recruitingPHASE1, PHASE2NCT05660408
RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Florida
- Principal Investigator
- John Ligon, MDUniversity of Florida
- Intervention
- pp65 RNA LP (DP1)(biological)
- Enrollment
- 36 enrolled
- Eligibility
- 3-39 years · All sexes
- Timeline
- 2025 – 2035
Study locations (1)
- UF Health, Gainesville, Florida, United States
Collaborators
The V Foundation for Cancer Research · National Pediatric Cancer Foundation · Alex's Lemonade Stand Foundation · The Osteosarcoma Institute · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05660408 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.
- RECRUITINGPHASE1, PHASE2NCT06892678DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaMontefiore Medical Center
- RECRUITINGPHASE2NCT06650514A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade OsteosarcomaVall d'Hebron Institute of Oncology